Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2013

View Archived Issues

Abbott, Janssen and Pharmacyclics collaborate on companion test for leukemia therapy

KineMed, Isis Pharmaceuticals and CHDI Foundation form biomarker collaboration

NIH-funded trial of Shigella vaccine candidates to commence

New ACC1 inhibitors disclosed by Bayer Intellectual Property

University of Colorado and Orphan Technologies expand collaboration

FDA grants priority review to Epigenomics' PMA for Epi proColon

Zeria announces the Japanese launch of agent for hypophosphatemia

BioMarin licenses factor VIII gene therapy program for hemophilia A

Novel MPGES-1 inhibitors show promising anti-inflammatory properties

Novo Nordisk plans launch of Tresiba in Japan

Novel PAF receptor antagonists demonstrate neuroprotective properties

Abbott Laboratories synthesizes novel GlyT-1 inhibitors

Daiichi Sankyo discloses new hypoglycemic agents

Novel MAb shows potency as plasma kallikrein inhibitor

Novel RORgamma modulators patented by Tempero Pharmaceuticals

Biota Scientific Management presents new antiviral agents

Meda to begin phase II flupirtine trial in fibromyalgia

Pentraxin-related protein PTX3 levels are associated with carotid plaque vulnerability

EMA confirms decision on VIVUS' MAA for obesity treatment

Trastuzumab emtansine obtains first approval

NINDS funds tumor cell proliferation research at The Scripps Research Institute

Novartis terminates OX-17 program agreement with Orexo

NR2 peptide plasma assay as a new diagnostic tool for acute cerebrovascular events

Taxol approved for new indication in Japan

Phase III trial of cilengitide in glioblastoma fails to meet primary endpoint

Ablynx and Spirogen form anticancer drug conjugate collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...